Request a Call

Request a Call from a

Information for:


Click here if you are a healthcare professional and would like more information on Pradaxa® (dabigatran etexilate)

Information intended for:


Click here for more information on Pradaxa®

PC-GB -101423 V1 January 2021

Immediate, complete and sustained
reversal of Pradaxa®(dabigatran etexilate)1–5

What is Praxbind® (idarucizumab)?

Praxbind® is a targeted antidote to dabigatran. As the specific reversal agent for dabigatran, Praxbind® is indicated in adult patients treated with Pradaxa® when rapid reversal of the anticoagulant effects of Pradaxa® is required.1

Praxbind® (idarucizumab) opened packaging
Praxbind® (idarucizumab) opened packaging

Why Pradaxa® reversal matters

Pradaxa® reversal with Praxbind® provides reassurance in cases of emergency surgery or urgent procedures and in instances of life-threatening or uncontrolled bleeding.1

Praxbind®: A reason
to prescribe Pradaxa®

Pradaxa® is the only NOAC with a specific reversal agent, Praxbind®, for emergency surgery/urgent procedures and life-threatening or uncontrolled bleeding. Consequently, Praxbind® provides the reassurance of immediate, complete and sustained reversal of the anticoagulant effects of Pradaxa, when required in emergency situations.1–5 As the specific reversal agent for Pradaxa®, Praxbind® is included on the National Antidote List and must be available within 1 hour to all Emergency Departments within UK hospitals.6

Emergency Surgery/ Urgent procedures – Life-threatening or uncontrolled bleeding
Emergency Surgery/ Urgent procedures – Life-threatening or uncontrolled bleeding
Included on the National Antidote List
Included on the National Antidote List
Pradaxa® (dabigatran etexilate) Reversibility: Complete/Immediate/Sustained
Pradaxa® (dabigatran etexilate) Reversibility: Complete/Immediate/Sustained

Praxbind® dosing and administration

Reversal of the anticoagulant effects of dabigatran is achieved with a fixed, ready-to-use IV dose of 5g Praxbind®. A fixed dose of Praxbind® ensures reversal of dabigatran for all patients. This means that you never have to worry about calculating dose adjustments according to the Pradaxa® dose administered or time since last Pradaxa® dose, or patient characteristics such as age and renal or hepatic impairment.1

Praxbind® mechanism of action

Idarucizumab is a humanised monoclonal antibody fragment (Fab) that binds to dabigatran with very high affinity - 300 times more potent than the binding affinity of dabigatran for thrombin. Idarucizumab potently and specifically binds to dabigatran and its metabolites and neutralises their anticoagulant effect, rapidly eliminating it from the body.1 

Idarucizumab is specific for dabigatran and can be used together with any other supportive measures or treatments required to manage patients on Pradaxa® with life-threatening bleeding or those requiring emergency surgery.1 Praxbind® takes dabigatran out of the equation, allowing physicians to focus on other aspects of emergency patient management. 

Praxbind (idarucizumab) mechanism of action
Praxbind (idarucizumab) mechanism of action

Watch the mechanism of action of Praxbind® in the video below to see how it brings about the reversal of dabigatran.


IV — Intravenous

NOAC — non-vitamin K antagonist oral anticoagulant

  1. Praxbind® Summary of Product Characteristics.
  2. Pollack CV, et al. N Engl J Med 2017;377(5):431–441.
  3. Schiele F, et al. Blood 2013; 121(18):3554-3562.
  4. Pradaxa® 150mg hard capsules Summary of Product Characteristics.
  5. Pradaxa® 110mg hard capsules Summary of Product Characteristics.
  6. Royal College of Emergency Medicine and National Poisons Information Service.
    Guideline on Antidote Availability for Emergency Departments (January 2017).
PC-GB-100767 V2 | March 2021


You are about to leave the Boehringer Ingelheim site for a site not created, managed or maintained by Boehringer Ingelheim.

Boehringer Ingelheim hopes that this link will be of interest and use to visitors, but it accepts no liability in relation to the website or its contents and gives no warranty as to the accuracy or completeness of information, data or reports on the website, to the fullest extent that any such liability may be lawfully excluded. Nor does Boehringer Ingelheim necessarily endorse or support any content on the third party website or any further links from their website.